In the last trading session, 1.05 million Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) shares changed hands as the company’s beta touched 0.21. With the company’s per share price at $1.25 changed hands at $0.01 or 0.81% during last session, the market valuation stood at $9.92M. BCLI’s last price was a discount, traded about -547.2% off its 52-week high of $8.09. The share price had its 52-week low at $0.72, which suggests the last value was 42.4% up since then.
Analysts gave the Brainstorm Cell Therapeutics, Inc (BCLI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BCLI as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) trade information
Instantly BCLI was in green as seen at the end of in last trading. With action 15.74%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -44.93%, with the 5-day performance at 15.74% in the green. However, in the 30-day time frame, Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) is 5.93% up.
Brainstorm Cell Therapeutics, Inc (BCLI) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 32.00%. The 2025 estimates are for Brainstorm Cell Therapeutics, Inc earnings to increase by 30.74%, but the outlook for the next 5-year period is at 29.48% per year.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 2.1212% or 1.51 million shares worth $0.51 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund. With 31.71 shares estimated at $39642.0 under it, the former controlled 0.40% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 0.34% of the shares, roughly 26.73 shares worth around $33417.0.
